SCHEMBL3662492

SCHEMBL3662492

COC(=O)C1CCN(c2ncc(B3OC(C)(C)C(C)(C)O3)cn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 5/20 0.48
MEN1 O00255 3/20 0.42
KMT2A Q03164 3/20 0.42
MAPT P10636 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
KCNMA1 Q12791 1/20 0.41
USP30 Q70CQ3 1/20 0.41
DGAT1 O75907 1/20 0.40
LMNA P02545 1/20 0.40
ALDH1A1 P00352 3/20 0.38
HPGD P15428 1/20 0.38
CYP2C19 P33261 2/20 0.38
NEK2 P51955 1/20 0.38
CYP3A4 P08684 1/20 0.37
CYP2C9 P11712 1/20 0.37
RAB9A P51151 1/20 0.37
HSD17B10 Q99714 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
TP53 P04637 1/20 0.36
TSHR P16473 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25447223 0.93 KDM4E (0.44) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL18450235 0.93 KDM4E (0.44) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL1844415 0.87 PTPN11 (0.47) KDM4EMEN1KMT2AMAPTSMN1; SMN2
SCHEMBL3659822 0.86 KDM4E (0.43) KDM4EMEN1KMT2AMAPTUSP30
SCHEMBL2180545 0.83 USP30 (0.45) KDM4EMEN1KMT2AUSP30DGAT1
SCHEMBL25169752 0.82 KDM4E (0.45) KDM4EMEN1KMT2AUSP30ALDH1A1
SCHEMBL25172509 0.82 KDM4E (0.45) KDM4EMEN1KMT2AUSP30ALDH1A1
SCHEMBL30313340 0.81 USP30 (0.48) KDM4EUSP30DGAT1CYP2C19
SCHEMBL1840795 0.81 SMO (0.38) KDM4EKCNMA1USP30DGAT1LMNA
SCHEMBL23551462 0.81 MAPT (0.58) KDM4EMEN1KMT2AMAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12559492-B2 BRAF degraders C4 THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-20230145336-A1 BRAF DEGRADERS C4 THERAPEUTICS, INC. (US) 2023-05-11 US disclosed
EP-4168407-A1 BRAF DEGRADERS C4 Therapeutics, Inc. (US) 2023-04-26 EP disclosed
EP-2231653-B1 ANTIBACTERIAL CONDENSED THIAZOLES BIOTA EUROPE LTD (GB) 2013-04-03 EP disclosed
US-8299065-B2 Antibacterial condensed thiazoles BIOTA EUROPE LTD. (GB) 2012-10-30 US disclosed
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES BIOTA EUROPE LTD (GB) 2010-12-02 US disclosed
EP-2231653-A1 ANTIBACTERIAL CONDENSED THIAZOLES Biota Europe Ltd (GB) 2010-09-29 EP disclosed
WO-2009074812-A1 ANTIBACTERIAL CONDENSED THIAZOLES PROLYSIS LTD (GB) 2009-06-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12559492-B2 BRAF degraders BRAF, NRAS, HRAS KDM4E 1258/4885MEN1 1552/4885KMT2A 1091/4885
US-20230145336-A1 BRAF DEGRADERS BRAF, NRAS, RAF1 KDM4E 332/4885MEN1 512/4885KMT2A 738/4885
US-20100305067-A1 ANTIBACTERIAL CONDENSED THIAZOLES NEK6, NEK1, TXK KDM4E 3573/4885MEN1 2077/4885KMT2A 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.